Cargando…

Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia

BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as...

Descripción completa

Detalles Bibliográficos
Autores principales: Alemu, Ayinalem, Tadesse, Mengistu, Seid, Getachew, Mollalign, Helina, Eshetu, Kirubel, Sinshaw, Waganeh, Abebaw, Yeshiwork, Amare, Misikir, Dagne, Biniyam, Diriba, Getu, Yenew, Bazezew, Getu, Melak, Zerihun, Betselot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993378/
https://www.ncbi.nlm.nih.gov/pubmed/32000702
http://dx.doi.org/10.1186/s12879-020-4817-2
_version_ 1783493019885895680
author Alemu, Ayinalem
Tadesse, Mengistu
Seid, Getachew
Mollalign, Helina
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Amare, Misikir
Dagne, Biniyam
Diriba, Getu
Yenew, Bazezew
Getu, Melak
Zerihun, Betselot
author_facet Alemu, Ayinalem
Tadesse, Mengistu
Seid, Getachew
Mollalign, Helina
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Amare, Misikir
Dagne, Biniyam
Diriba, Getu
Yenew, Bazezew
Getu, Melak
Zerihun, Betselot
author_sort Alemu, Ayinalem
collection PubMed
description BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results. METHODS: Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample. RESULTS: A total of 100 specimens were reported as MTB Detected Rifampicin Resistance Detected by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations. CONCLUSION: Mutations associated with Probe E (codons 529–533) region were identified as the commonest rpoB gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum.
format Online
Article
Text
id pubmed-6993378
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69933782020-02-04 Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia Alemu, Ayinalem Tadesse, Mengistu Seid, Getachew Mollalign, Helina Eshetu, Kirubel Sinshaw, Waganeh Abebaw, Yeshiwork Amare, Misikir Dagne, Biniyam Diriba, Getu Yenew, Bazezew Getu, Melak Zerihun, Betselot BMC Infect Dis Research Article BACKGROUND: Xpert® MTB/RIF assay is currently used in Ethiopia for the rapid diagnosis of Mycobacterium tuberculosis (MTB) and mutations that confer Rifampicin resistance. Rifampicin resistance is determined based on any mutation in the 81 bp of rpoB gene using five overlapping probes represented as Probe A (codons 507–511), Probe B (codons 512–518), Probe C (codons 518–523), Probe D (codons 523–529) and Probe E (codons 529–533). In this review, we assessed the frequency of missed probe types for Rifampicin Resistance results. METHODS: Data were reviewed from specimens received and tested using Xpert® MTB/RIF assay at Ethiopian National Tuberculosis Reference Laboratory, in Addis Ababa from 15 July 2016 to 31 December 2018 retrospectively. All archived data were reviewed carefully to describe missed probe types and the quantity of DNA in the sample. RESULTS: A total of 100 specimens were reported as MTB Detected Rifampicin Resistance Detected by Xpert® MTB/RIF assay. More than half (55%) of these results were reported from male patients. The median age was 28.0 years (5 months to 88 years). Majorities (62%) of the cases were detected from sputum. Among the total of 38 extrapulmonary samples, lymph node aspirates were accounted for 50% (19/38). The most common mutations (81.0%) were found in the Probe E region followed by Probe D (10.0%), and Probe B (3.0%). Mutations in Probe A and Probe C regions were not observed. However, six (6.0%) Rifampicin resistance cases were found without any missed probe type. The delta Ct max is ≥4.3. No specimen yielded Rifampicin resistance associated with more than one probe failure or mutation combinations. CONCLUSION: Mutations associated with Probe E (codons 529–533) region were identified as the commonest rpoB gene mutations. The Rifampicin resistance results found without any identified missing probe needs further study. The lower DNA amount was observed in extrapulmonary specimens compared with sputum. BioMed Central 2020-01-30 /pmc/articles/PMC6993378/ /pubmed/32000702 http://dx.doi.org/10.1186/s12879-020-4817-2 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Alemu, Ayinalem
Tadesse, Mengistu
Seid, Getachew
Mollalign, Helina
Eshetu, Kirubel
Sinshaw, Waganeh
Abebaw, Yeshiwork
Amare, Misikir
Dagne, Biniyam
Diriba, Getu
Yenew, Bazezew
Getu, Melak
Zerihun, Betselot
Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title_full Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title_fullStr Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title_full_unstemmed Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title_short Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
title_sort does xpert® mtb/rif assay give rifampicin resistance results without identified mutation? review of cases from addis ababa, ethiopia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993378/
https://www.ncbi.nlm.nih.gov/pubmed/32000702
http://dx.doi.org/10.1186/s12879-020-4817-2
work_keys_str_mv AT alemuayinalem doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT tadessemengistu doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT seidgetachew doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT mollalignhelina doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT eshetukirubel doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT sinshawwaganeh doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT abebawyeshiwork doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT amaremisikir doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT dagnebiniyam doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT diribagetu doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT yenewbazezew doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT getumelak doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia
AT zerihunbetselot doesxpertmtbrifassaygiverifampicinresistanceresultswithoutidentifiedmutationreviewofcasesfromaddisababaethiopia